In the presented work, five bio-based and bio-degradable cyclic esters, i.e. lactones, have been investigated as possible phase change materials for applications in latent heat storage systems. Commercial natural lactones such as ε-caprolactone and γ-valerolactone were easily purchased through chemical suppliers, while 1,2-campholide, oxa-adamantanone and dibenzochromen-6-one were synthesized through Baeyer-Villiger oxidation. The compounds were characterized with respect to attenuated total reflectance spectroscopy and gas chromatography coupled with mass spectroscopy, in order to confirm their chemical structures and identity. Subsequently, thermogravimetric analysis and differential scanning calorimetry were used to measure the phase change temperatures, enthalpies of fusion, degradation temperatures, as well to estimate the degree of supercooling. The lactones showed a wide range of phase change temperatures from -40 °C to 290 °C, making them a high interest for both low and high temperature latent heat storage applications, given the lack of organic phase change materials covering phase change temperature ranges below 0 °C and above 80 °C. However, low enthalpies of fusion, high degrees of supercooling and thermal degradations at low temperatures were registered for all samples, rendering them unsuitable as phase change materials.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6479808 | PMC |
http://dx.doi.org/10.3390/molecules24071300 | DOI Listing |
Background: Alzheimer's disease (AD) agitation is a distressing neuropsychiatric symptom characterized by excessive motor activity, verbal aggression, or physical aggression. Agitation is one of the causes of caregiver distress, increased morbidity and mortality, and early institutionalization in patients with AD. Current medications used for the management of agitation have modest efficacy and have substantial side effects.
View Article and Find Full Text PDFBackground: Lecanemab is a humanized IgG1 monoclonal antibody that binds with high affinity to Aβ soluble protofibrils. In two clinical studies (phase 2, NCT01767311 and phase 3 ClarityAD, NCT03887455) in early Alzheimer's disease, lecanemab substantially reduced amyloid PET and significantly slowed clinical decline on multiple measures of cognition and function, including CDR-SB at 18 months. Models describing the change in amyloid PET and CDR-SB in response to lecanemab treatment were used to explore the impact of changing from the initial dosage regimen (10 mg/kg every 2 weeks [Q2W]) to a less intensive maintenance dosing regimen (10 mg/kg every 4 weeks [Q4W]) on clinical efficacy, and to explore the optimal duration of the initial dosing regimen.
View Article and Find Full Text PDFBackground: Alzheimer's disease (AD) is a progressive neurodegenerative disease characterized by the formation of amyloid-beta (Aβ) plaques and neurofibrillary tangles (NFTs) composed of tau aggregates. Research in animal models has generated hypotheses on the underlying mechanisms of the interaction between Aβ and tau pathology. In support of this interaction, results from clinical trials have shown that treatment with anti-Aβ monoclonal antibodies (mAbs) affects tau pathology.
View Article and Find Full Text PDFBackground: In Alzheimer's Disease trials, the Mini-Mental State Examination (MMSE) and Clinical Dementia Rating (CDR) are commonly utilized as inclusionary criteria at screening. These measures, however, do not always reaffirm inclusionary status at baseline. Score changes between screening and baseline visits may imply potential score inflation at screening leading to inappropriate participant enrollment.
View Article and Find Full Text PDFBackground: CT1812 is an experimental therapeutic sigma-2 receptor modulator in development for Alzheimer's disease (AD) and dementia with Lewy bodies. CT1812 reduces the affinity of Aβ oligomers to bind to neurons and exert synaptotoxic effects. This phase 2, multi-center, international, randomized, double-blind, placebo-controlled trial assessed safety, tolerability and effects of CT1812 on cognitive function in individuals with AD.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!